{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:18:20Z","timestamp":1779106700667,"version":"3.51.4"},"reference-count":0,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1992,11]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Based on the results of our phase I study that demonstrated the antitumor activity of taxol in a previously treated patient with ovarian cancer, a phase II study was conducted to evaluate the efficacy of taxol in patients with metastatic ovarian cancer and to evaluate further the toxicity of taxol in this group of patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> Thirty-four patients with metastatic ovarian cancer received taxol (180 to 250 mg\/m2) as a 24-hour continuous infusion. A premedication regimen was used to reduce the likelihood of an acute hypersensitivity reaction. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Six of 30 assessable patients demonstrated complete responses (one patient) or partial responses (five patients; 20%; 95% confidence interval [CI], 6% to 34%; range, 2 to 30 months). Additionally, one patient had a less than partial objective response (2 months), and two patients had stable disease for 6 and 15 months. Those responders had a median survival of 27 months, and the nonresponders had a median survival of 6 months (P = .0001). Myelosuppression was the most significant toxicity. Other adverse effects included alopecia and peripheral neuropathy. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> Taxol has significant activity in ovarian cancer and should be studied in combination with other active agents earlier in this disease. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.1992.10.11.1748","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T14:36:30Z","timestamp":1487860590000},"page":"1748-1753","source":"Crossref","is-referenced-by-count":185,"title":["Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma."],"prefix":"10.1200","volume":"10","author":[{"given":"A I","family":"Einzig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P H","family":"Wiernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Sasloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C D","family":"Runowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G L","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1992.10.11.1748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T19:59:20Z","timestamp":1653508760000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1992.10.11.1748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,11]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1992,11]]}},"alternative-id":["10.1200\/JCO.1992.10.11.1748"],"URL":"https:\/\/doi.org\/10.1200\/jco.1992.10.11.1748","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,11]]}}}